Healthcare Services PE Stops Compounding

What's New

PitchBook's Q2 2026 Healthcare Services Report shows healthcare services deal count down 18.5% year over year in the second quarter, with weakness spreading across three of the four segments the firm tracks. The headline decline understates what actually happened. Deal value across the first half fell only 7.3%, which means fewer but larger transactions carried the period, anchored by KKR's $3.4 billion IPO of Global Medical Response and Knox Lane's $416 million take private of Cross Country Healthcare. The more consequential datapoint sits further into the report: the total count of PE backed healthcare services companies is running at essentially 2025 levels, which would mark the first year on record without growth in the installed base. Entry multiples and entry leverage both kept climbing through the slowdown, so the assets that did trade got more expensive and more levered even as volume collapsed. This is not a market repricing. It is a market that has stopped clearing.

Why It Matters

A flat company count with a falling exit count is a math problem, not a sentiment problem. Exit count is pacing 26.5% below 2025 and exit value 30.9% below, which means capital is not returning to LPs on schedule while the underlying portfolio ages in place. Sponsors facing that arithmetic have three levers: hold longer and defend margin, recapitalize at higher leverage, or accept a wider bid ask spread on exit. All three raise the operational and reporting burden on the platform layer, and all three make the quality of position level data materially more valuable than it was in a market where exits solved for everything.

Big Picture Drivers

• Regulatory encirclement of the MSO structure: California's AB 1415 took effect on January 1 with a 90 day advance notice requirement and detailed financial and governance disclosure, and the implementing regulations have not even been written yet. Rhode Island, Oregon, Hawaii, Pennsylvania, Indiana, New York, Vermont, and Virginia are all moving in the same direction, targeting corporate practice of medicine restrictions and the friendly physician model directly.

• Utilization and coverage shock: Soft hospital volumes trace to reduced ACA exchange premium subsidies and tighter Medicaid eligibility, which is a coverage driven demand contraction rather than a cyclical one. It does not self correct with rates.

• The exit channel is the binding constraint: With exits down roughly a third by value, the pressure lands on holding periods rather than on marks, which is the slower and less visible way for a vintage to disappoint.

• Aged inventory has reached scale: Dental, mental health, home based care, MSK, clinical staffing, and dermatology each carry at least 20 companies held seven years or more. Veterinary is the leading indicator, with 16 companies past seven years and another 50 sitting in the five to seven year band.

• Rate expectations moving the wrong way: The report frames the quarter against the prospect of rate hikes rather than cuts, which removes the refinancing exit that carried a lot of 2024 and 2025 planning assumptions.

• Divergence favors infrastructure over practices: Clinical staffing, diagnostic laboratories, and ambulatory surgical centers held up while physician practice roll ups did not, suggesting capital is rotating toward assets that sell capacity rather than assets that require clinician alignment.

By The Numbers

• 71 PPM deals, extrapolated for the quarter: Down from 89 in Q1, 102 in Q4 2025, and 111 in Q2 2025, a 35.8% annual decline in what remains the largest segment in the sector.

• 54.4%: The pace at which generalist and multispecialty provider deal count is tracking below 2025, the steepest fall of any segment, against ancillary and outsourced services at only 4.9% below.

• 13.6x and 5.2x: Median entry enterprise value to EBITDA and median entry net debt to EBITDA for 2025, both series highs, versus 10.3x and 4.6x in 2017. Price and leverage rose together.

• $162.5 million at a 20.5% EBITDA margin: Median revenue and margin at entry for 2025, up from $147.1 million and 17.8% a year earlier. Sponsors are buying larger and cleaner assets, which is what happens when only the best businesses can clear a process.

• 61.3% versus 31.1%: Median year to date returns for value based care and payers respectively, both far ahead of providers, whose shares lagged the broader market on weak utilization.

• 10x: Where public hospital EV to trailing EBITDA multiples sit, right at the long term average, meaning the public market has not marked the sector down even as private volume has evaporated.

Key Trends to Watch

• State by state compliance becomes a diligence line item: Notice periods running from 90 to 180 days, with regulators able to extend review, effectively add two quarters to serial acquisition programs. Expect deal structuring and legal cost to compress the returns on add on strategies before it stops them outright.

• The reorganization wave arrives before the recovery does: PitchBook cites counsel observing a pickup in reorganization and cleanup engagements as an early signal for renewed activity, which typically means restructuring volume leads transaction volume by two to three quarters.

• Agentic AI as the PPM thesis reset: The report argues PPMs are long term beneficiaries of throughput and efficiency gains from agentic AI, with return profiles materially better than historical once operating playbooks adapt. Watch for the first sponsor to underwrite that explicitly rather than retrospectively.

• Demographics carry elder care through the downturn: Strength in elder care is expected to persist on demographic support and strategic acquirer interest, making it the most likely segment to see competitive processes return first.

• Vision, fertility, ABA, and IDD as counterpositioning: These are the only subsegments pacing to beat 2025 inside otherwise falling categories, and they share a common trait of payer diversity and lower hospital dependence.

The Wrap

The Q2 story is not that healthcare services PE got cheaper. It is that the sector's growth engine, continuous platform formation and add on accumulation, has been throttled simultaneously by regulation, coverage contraction, and a closed exit window, while the assets already in the ground get older and more levered. The next twelve months will be an operating story rather than a transaction story, and the sponsors who fare best will be the ones who can prove portfolio company performance rather than argue for it. For technology providers, that shifts the buying center: the demand is no longer for deal sourcing and screening but for position level monitoring, holding period analytics, leverage and covenant visibility, and defensible valuation support across a portfolio that has to be marked and defended for longer than anyone underwrote. Platforms that treat private markets data as a transaction workflow will be selling into the part of the market that has stopped moving.